| Autor: |
Roy S; Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India., Pathy S, Mohanti BK, Chander S, Biswas A |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of pediatric hematology/oncology [J Pediatr Hematol Oncol] 2017 Mar; Vol. 39 (2), pp. e62-e68. |
| DOI: |
10.1097/MPH.0000000000000745 |
| Abstrakt: |
The study was aimed at evaluating adherence to treatment protocol and outcome in pediatric parameningeal rhabdomyosarcoma (PM-RMS). We analyzed the characteristics, treatment administered, outcomes and patterns of failure of pediatric PM-RMS, who were treated with multimodality therapy between January 2005 and December 2013.Univariate and multivariate analysis (MVA) was completed to evaluate the impact of various prognostic factors. Thirty-seven patients were treated at our institution. Majority of them had the primary disease in paranasal sinuses (n=13). Majority of the patients belonged to group III (n=30) and stage III (n=24). The overall response rate to treatment was 52.5% (n=21). At a mean follow-up of 19.1 months, 23 patients developed disease progression. The actuarial rates of failure-free survival and overall survival (OS) at 2 years were 40% and 67.5%, respectively. Patients who received >20 weeks of intended chemotherapy schedule (P=0.02) and had complete response to first-line treatment (P=0.0004) were found to have superior failure-free survival on MVA. Complete response was the lone determinant of superior OS on MVA (P=0.006). Majority of patients with PM-RMS present with advanced stage disease. Response to first-line treatment is a significant predictor of superior progression-free survival and OS in these patients. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
